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Abstract
TWEAK (tumor necrosis factor-like weak inducer of apoptosis) is a member of the TNF superfamily that controls a multitude 
of cellular events including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. TWEAK 
control of these events is via an expanding list of intracellular signalling pathways which include NF-κB, ERK/MAPK, 
Notch, EGFR and AP-1. Two receptors have been identified for TWEAK – Fn14, which targets the membrane bound form 
of TWEAK, and CD163, which scavenges the soluble form of TWEAK. TWEAK appears to elicit specific events based on 
the receptor to which it binds, tissue type in which it is expressed, specific extrinsic conditions, and the presence of other 
cytokines. TWEAK signalling is protective in healthy tissues, but in chronic inflammatory states become detrimental to the 
tissue. Consistent data show a role for the TWEAK/FN14/CD163 axis in metabolic disease, chronic autoimmune diseases, 
and acute ischaemic stroke. Low circulating concentrations of soluble TWEAK are predictive of poor cardiovascular out-
comes in those with and without diabetes. This review details the current understanding of the TWEAK/Fn14/CD163 axis as 
one of the chief regulators of immune signalling and its cell-specific role in metabolic disease development and progression.
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1 Introduction
Members of the tumor necrosis factor (TNF) superfamily of 
cytokines are typically expressed as type 2 transmembrane 
proteins with homologous TNF domains. They are directly 
involved in immune responses and inflammation, in addition 
to proliferation, differentiation, apoptosis, and embryogen-
esis, and have consequently received attention as potential 
drug targets in recent years [1, 2].
TWEAK (TNFSF12) and its known receptor Fn14 
(TNFRSF12A) have been identified as members of the TNF 
and TNF receptor (TNFR) family of cytokines, respectively 
[1]. A second scavenger receptor for TWEAK, CD163, has 
also been identified in recent years [3]. There is growing 
evidence of direct TWEAK/Fn14/CD163 involvement in 
several autoinflammatory pathologies across several tissue 
and cell types; however, the exact impact of TWEAK/Fn14/
CD163 on disease development remains poorly understood. 
Recently, new functions for the TWEAK/Fn14/CD163 axis 
have become apparent, including the control of synaptic 
transmission and formation of atherosclerotic plaques [4, 5]. 
Here, we review the latest understanding of TWEAK/Fn14/
CD163 as one of the chief regulators in immune signalling 
and its cell-specific role in metabolic disease development 
and progression.
2  Structure of tweak and its receptors
In 1997, TWEAK was first identified as a novel, highly 
conserved and pro-apoptotic TNF-like protein in interferon 
gamma (IFNg) treated human HT-29 colon carcinoma cells 
[1, 6]. TWEAK exists in two forms—as a full-length mem-
brane bound (mTWEAK) protein consisting of 246 amino 
acids, or as a 156-amino. acid soluble protein (sTWEAK) 
generated by furin proteolysis of TWEAK (Fig. 1a) [1, 7]. 
TWEAK has an intercellular N-terminal domain with a 
potential protein kinase C phosphorylation site, a transmem-
brane domain and an extracellular TNF homology domain 
(THD) located on the C-terminus [8]. TWEAK is also the 
only member of the TNF family which can bind the cognate 
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Fn14 receptor – the smallest member of TNF receptor super-
family – and trigger signalling which can lead to growth and 
proliferation, angiogenesis, and in an inflammatory scenario, 
stimulation of apoptosis [9].
The extracellular ligand-binding region of Fn14 is 
composed of 53 amino acid residues and forms a single, 
cysteine-rich domain (CRD) similar to that of the fourth 
CRD of TNF receptor 1, which is a ubiquitous membrane 
receptor that binds TNFa (Fig. 1b) [8, 10]. The promoter 
region has multiple nuclear factor-kappaB (NF-κB) bind-
ing sites, enabling positive feedback regulation between 
Fn14 and NF-κB [11]. Protein modelling has revealed that 
intracellular signalling is only triggered after TWEAK binds 
to the receptor and enables trimerization of the TWEAK/
Fn14 complex, which is enhanced by complementary bind-
ing interactions caused by opposing charge and hydrophobic 
residues [12]. Trimerization leads to higher order receptor 
clustering, activation of signalling and recruitment of intra-
cellular adaptor proteins into the vicinity of the receptor 
[13]. Fn14 expression is normally low in healthy tissues and 
cells, but becomes upregulated in the event of injury, oxi-
dative stress and inflammation [14, 15]. Numerous stimuli 
including endothelial growth factor, IFNγ, IL1β, thrombin 
and angiotensin can stimulate Fn14 expression [1]. Bacterial 
Fig. 1  Structure of TWEAK and receptors. A Schematic represen-
tation of (a) membrane bound and soluble TWEAK produced and 
secreted by numerous cells type, mostly notably by monocytes, (b) 
the membrane Fn14 receptor expressed by several cells including 
endothelial cells and only detectable in large quantities in the event of 
cellular stress or injury, and (c) the CD163 receptor expressed exclu-
sively on macrophages. The two receptors and TWEAK all contain 
transmembrane, intracellular and extracellular domains with CD163 
and TWEAK existing in soluble forms. Localisation of the cellular 
TWEAK, CD163 and Fn14 axis interaction leads to different biologi-
cal responses
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LPS also induces expression of Fn14 in SIEC02 cells in 
a TNFα-dependent manner [16]. However, TWEAK can 
suppress LPS-induced Fn14 expression in cells and reduce 
proinflammatory cytokine production [12]. Interestingly, 
when upper threshold levels of Fn14 expression are reached, 
TWEAK is no longer required to bind and initiate signal-
ling and Fn14 can behave in a ligand-independent manner, 
activating the NF-κB pathway unilaterally [17].
The type I transmembrane scavenger receptor CD163 
has been proposed as a scavenger receptor for TWEAK [3]. 
CD163 is expressed exclusively on the cells of the mono-
cytic–macrophage linage and has been identified as the sec-
ondary, decoy receptor for TWEAK [3]. CD163 is a 1048 
amino acid long membrane protein with a cytoplasmic tail, 
a single transmembrane section, and nine cysteine-rich scav-
enger receptor class B domains (Fig. 1c) [18]. It indirectly 
contributes to the anti-inflammatory response and can exist 
in various isoforms. Elevated plasma CD163 expression 
in macrophages is associated with increased inflamma-
tory response sites [19]. CD163 binds to and internalises 
the available pool of sTWEAK which leads to regulation of 
TWEAK-induced activation of canonical NF-κB and Notch 
signalling needed for myogenic progenitor cell proliferation 
[20, 21]. There is growing evidence that differences in the 
concentrations of available mTWEAK and sTWEAK may 
have an impact on disease progression and outcome [22]. 
Patients with coronary artery disease, heart failure, chronic 
kidney disease and diabetes mellitus have been reported to 
have low levels of sTWEAK and increased Fn14 expres-
sion [22, 23]. However, the role of CD163 in this context 
has not been well investigated and the downstream effect of 
TWEAK/CD163 interaction is also unclear.
The biological effects of TWEAK appear to be cell and 
concentration dependent [24]. TWEAK is suggested to have 
a beneficial role in the acute, pathological environment by 
encouraging muscle repair. However, little is known about 
how TWEAK itself is regulated and which TWEAK regu-
lated downstream pathways lead to repair and regeneration 
and which environments favour opposing effects.
3  Tweak regulation of signalling pathways
3.1  Canonical and non‑canonical NF‑κB pathways
The majority of the currently known functions of TWEAK 
are connected to expression of TWEAK-induced proinflam-
matory cytokines, chemokines, and cell adhesion molecules, 
predominantly through the activation of the NF-κB path-
way, which is a highly regulated proinflammatory transcrip-
tion factor that controls the expression of over 400 genes 
[25, 26]. TWEAK appears to be involved in the regulation 
of a multitude of genes; in vascular smooth muscle cells 
(VSMC) alone, it has been shown to upregulate 1611 and 
down regulate 1091 genes [27]. There is discussion around 
which pathways are influenced and regulated by TWEAK 
and what genes are affected; however, NF-κB pathway acti-
vation through Fn14 receptor signalling is the one in which 
the role of TWEAK is best understood. CD163 binding to 
sTWEAK has been shown to regulate the NF-κB pathway 
to some extent [21].
Binding of TWEAK to Fn14 recruits cellular inhibitor of 
apoptosis (cIAP1), TRAF2, TRAF5, and/or TRAF6 into a 
complex to activate transforming growth factor B-activated 
kinase 1 (TAK1), NF-κB -inducing kinase (NIK), and mito-
gen activated protein kinase kinases (MKK) [28]. Activation 
of TGF-B-activated kinase-1 TAK1 stimulates IB kinase 
(IKKB) leading to the activation of the early canonical NF-κB 
pathway characterised by nuclear translocation of RelA [28, 
29]. NIK phosphorylates and activates IKKB leading to pro-
longed, but slower, activation of the non-canonical NF-κB 
pathway symbolised by increased DNA-binding activity of 
the p52/RelB NF-κB complex [23]. The non-canonical NF-κB 
pathway regulates immunity and disease development which 
is consistent with the ability of TWEAK to reduce innate 
response and its transition to adaptive TH1 immunity by curb-
ing production of IFNγ and IL12 [4, 30].
The non-canonical NF-κB pathway is activated by a 
significantly smaller number of TNFR superfamily mem-
bers—Fn14, TNFR2, BAFFR, CD40, LTBR, and RANK 
[28]. Many of these receptors can also activate the canonical 
NF-κB pathway and thus, intermediatory functional cooper-
ation between these two pathways is required [28]. Interest-
ingly, regardless of whichever NF-κB pathway is activated, 
the observed apoptotic behaviour of TWEAK is mediated 
through secreted TNFα, which via the TNFα-TNFR1 recep-
tor complex, activates downstream RIPK1-FADD-Caspase-8 
complex [31]. It was later proven that downregulation of 
otubain 1 (OTUB1) is needed to observe the TNFα media-
tion of apoptosis, as it enhances TWEAK or IAP antago-
nist‐stimulated c‐IAP1 degradation and decreases the level 
of apoptotic sensitivity [32].
3.2  ERK/MAPK, EGFR and AP‑1 signalling pathways
In addition to activating canonical and non-canonical 
NF-κB, TWEAK induces MAPK and activator protein-1 
(AP-1) signalling pathways [28]. The activation of these 
pathways is attained through several different MKKs which 
activate Jun N-terminal kinase 1 (JNK1) and p38 MAPK. 
These recruit transcription factors including transcription 
factor AP-1, which regulates expression of genes involved 
in TWEAK-regulated responses [28].
TWEAK- controlled pathway activation appears to be 
cell-type specific and context-dependent [33]. TWEAK 
has a proinflammatory effect in adipocytes; however, this 
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is mediated by NF-κB, and ERK pathways rather than JNK 
signalling [33]. TWEAK also increases proliferation in 
renal cells through activating the mitogen-activated protein 
kinases ERK and p38, the phosphatidyl-inositol 3-kinase 
(PI3K)/Akt pathway and NF-κB [34]. Anti-TWEAK mono-
clonal antibodies inhibit this proliferation through reduction 
in the expression of MAPK and NF-κB signalling as well as 
reducing AKT and p38 levels in autosomal dominant poly-
cystic kidney disease preclinical models [35, 36].
Research data presents EGFR transactivation as a 
novel pathway for TWEAK–Fn14‐induced inflamma-
tion in kidneys [37]. Silencing of the TNFRSF12A gene 
stops TWEAK‐induced EGFR phosphorylation and due to 
a lack of tyrosine kinase activity within the Fn14 recep-
tor, the EGFR pathway must be activated by intracellular 
mechanisms [37]. The same study indicates that binding of 
TWEAK to Fn14 activates ADAM17, a membrane‐anchored 
disintegrin and metalloproteinase important in kidneys, trig-
gering secretion of HB‐EGF and TGFa that in turn, transac-
tivates EGFR [30]. Inhibition of EGFR, ERK or ADAM17 
in vitro effectively inhibits TWEAK-induced production of 
pro-inflammatory cytokines suggesting a role for TWEAK 
in the ADAM17–EGFR–ERK pathway regulation of pro‐
inflammatory factor expression in a renal environment [37].
TWEAK, through mitogen activated protein kinase ERK 
and AKT signalling pathways, has been shown to impact 
cyclins (cyclinD1) and cyclin-dependent kinases (CDK4, 
CDK6) expression at both the protein and mRNA level 
and to decrease the expression of cyclin-dependent kinase 
inhibitors (p15lNK4B) in VSMCs, which is significant for 
regulation of proliferation [27]. Interestingly, inhibition of 
ERK1/2 activation by a MAPK kinase inhibitor has no effect 
on the TWEAK pro-calcific properties in VSMCs observed 
in chronic kidney disease, type 2 diabetes, and aging [38]. 
In the context of skeletal muscle, TWEAK has been shown 
to alter matrix metalloproteinase 9 (MMP-9) production 
through the activation of ERK1/2, JNK1, NF-κB -inducing 
kinase and p38 mitogen-activated protein kinase pathways 
[39]. The TWEAK induced increase in MMP-9 expression 
in myotubes was only impeded by the inhibition of p38 
MAPK [39].
3.3  Notch signalling
Notch signalling is a highly conserved signalling pathway 
almost universally present in every animal [40]. The activity 
of the receptor is highly regulated on all levels even at the 
post translational stage where numerous ubiquitin ligases 
and proteins, such as Numb are recruited to promote neural 
differentiation [40]. Notch signalling plays a significant role 
in embryonic development, determining the fate of T cell 
lineage from their lymphoid precursor [41]. Notch signalling 
is detected in the early stages of pancreatic development, 
where it directs the recruitment of endocrine cells from their 
progenitor cells, but many studies also indicate that its func-
tion extends to exocrine development [42]. Notch signalling 
has been implicated in several human pathologies of car-
diovascular origin as well as in numerous cancers [43–46].
TWEAK has been shown to also activate Notch signal-
ling through TWEAK-mediated activation of the canonical 
NF-κB pathway [21]. Interestingly the same study follows 
up with the effect CD163 has on TWEAK function, which 
is a relatively new area of exploration with the majority of 
studies focusing exclusively on Fn14 as the main modu-
lator. CD163 has been shown to scavenge and inactivate 
sTWEAK which leads to poor outcomes in ischemic mice 
[21]. TWEAK was effectively prevented from mediating 
tissue damage repair at and beyond the site of injury and 
the duration of TWEAK-induced activation of canonical 
NF-κB/Notch signalling was shortened, which limited the 
differentiation of the progenitor cells [21]. CD163 deficient 
ischemic mice on the other had increased levels of TWEAK 
and enhanced notch signalling which aided in repair.
4  Regulation of tweak expression 
and function
TWEAK expression and function appears to be controlled 
at multiple levels although regulation is poorly understood. 
TWEAK is similar to TNFα in that it is able to direct sev-
eral biological responses [1, 47, 48]. During steady state, 
TWEAK unlike TNFα, can be detected at higher expres-
sion levels and is expressed in several more tissues which 
include heart, brain, kidneys, and mononuclear blood cells 
[23, 49]. TWEAK mRNA, by comparison to other TNF 
superfamily members is also more stable, enabling longer 
and more stable signalling times [49]. TWEAK can exist as 
a part of hybrid transcript consisting of TWEAK and APRIL 
(TNFSF13) mRNAs [50]. The encoded TWE-PRIL protein 
is made up of TWEAK cytoplasmic and transmembrane 
domains attached to the APRIL C-terminal domain [50]. 
TWE-PRIL mRNA is expressed and translated in human 
primary T cells, monocytes, and endogenous TWE-PRIL 
protein was detected in primary human T lymphocytes and 
monocytic cell lines [50]. It has been proposed, yet still to 
be confirmed, that the hybrid mRNA is not a by-product and 
in fact its expression is tightly regulated by an unidentified 
factor [50]. The same study has shown that TWE-PRIL is a 
membrane-bound, biologically active protein which has no 
effect on apoptosis but enhances cell division and prolifera-
tion [50].
The expression of TWEAK mRNA is downregulated 
after treatment with LPS in murine peritoneal macrophages, 
but the opposite is observed in human THP-1 monocytic 
cells [1, 49]. TWEAK expression is quickly increased on 
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monocytes when stimulated with IFNγ but not with IFNα 
[51]. TRAF3IP2 mediates TWEAK autoregulation and 
TWEAK-induced p38 MAPK, NF-κB and AP-1 activation 
[48]. c‐IAP proteins, which are critical E3 ligases, are also 
essential for the proper functioning of TWEAK [52]. In their 
absence TWEAK signaling and gene expression are greatly 
diminished [52]. OTUB1 works by inhibiting cytokine gene 
transcription within the immune system and regulates c‐
IAP1 via K48‐linked polyubiquitination [53]. When OTUB1 
is downregulated, it leads to much faster degradation of c‐
IAP1 and as a consequence, weaker TWEAK signaling [52, 
53]. Interestingly, only canonical NF‐κB and MAPK sign-
aling are affected by the downregulation of OTUB1, which 
temporarily (as the non-canonical pathway is still functional) 
lowers the volume of produced cytokines including TNFα 
[32, 52]. TNFα is one of the most upregulated cytokines in 
these pathways, which on its own has no impact on c‐IAP1 
K48‐specific ubiquitination or c‐IAP1 degradation [32]. In 
the absence of OTUB1 TNFα does however induce further 
TWEAK or IAP antagonist‐stimulated c‐IAP1 degradation 
and increases apoptosis [32, 52].
The list of downstream regulatory molecules which 
inhibit or activate TWEAK is unknown. However, it appears 
that TWEAK itself can act as a molecular switch dependent 
on the presence of angiogenic cytokines to act as a potential 
proangiogenic or antiangiogenic agent [46]. This is consist-
ent with previous reports showing that TNF superfamily 
members can display seemingly dichotomous behaviors 
dependent on cellular conditions. During the early stages 
of acute inflammation, those cytokines and their receptors 
aid in the maintenance of homeostasis and encourage repair, 
whereas the opposing behavior of apoptosis and damage 
is observed during advanced chronic disease and inflam-
mation [54]. Post-translationally, TWEAK protein func-
tion has been connected to induction of angiogenesis, cell 
growth and production of inflammatory cytokines [55]. It 
has been described as a weak inducer of apoptosis; how-
ever, depending on the cell type, it can also stimulate pro-
liferation (for instance in liver cells and osteoblasts) [56]. 
This mirrors various mRNA expression responses to the 
same cytokines depending on the cell type. Little is known 
about how protein function is improved or maintained post-
translationally. NFAT1-LCN2 can effectively regulate and 
stabilise TWEAK at the protein level [57]. NFAT1 induces 
Lipocalin 2 (LCN2) mRNA and protein expression by bind-
ing to specific sites in the LCN2 gene promoter region and 
depending on the LCN2 expression, TWEAK displays either 
pro-tumorigenic or anti-tumorigenic behaviour [57]. NFAT1 
and LCN2 are speculated to participate in the regulation of 
an unknown TWEAK receptor as LCN2 is necessary for 
TWEAK to promote its pro-invasive effect; in its absence, 
TWEAK can only signal by Fn14 which leads to anti-
tumorigenic behaviour [57]. Poveda et al. have shown that 
TWEAK-induced NF-κB expression is regulated by Bcl3 
and its over expression stops TWEAK-induced inflammatory 
and lethal responses in cultured tubular cells [23]. Bcl3 is a 
NF-κB regulatory protein of the IκB family, which by ubiq-
uitination of P50 and P52, inhibits DNA binding and gene 
transcription [23]. P50 and P52 are important members of 
the non-canonical NF-κB through which TWEAK primarily 
signals [30].
Cell extrinsic factors such as hyperglycaemia or reactive 
oxygen species play an important role in the expression and 
stability of many of the proteins of the TNF superfamily 
[47]. Very little information is available on how and if these 
factors affect the expression of TWEAK directly. A study by 
Padrão et al. has demonstrated that regular exercise encour-
aged upregulation of PGC‐1a and oxidative phosphorylation 
complexes and simultaneously prevented TWEAK from dis-
playing its pro-invasive behaviour in the context of cancer 
[58]. Obesity and insulin resistance have also been identi-
fied as potential factors leading to lower plasma sTWEAK 
concentrations, which in the case of cardiovascular disease 
appear to be detrimental [59]. Further work is required to 
elucidate how extrinsic factors affect TWEAK expression 
and signalling.
5  Tweak and diabetes
One of the main problems associated with the lack of a per-
manent ‘cure’ for diabetes versus long term treatment as a 
way of managing the disease, is the fact that once damaged, 
beta cells have a limited ability to proliferate and expand to 
restore insulin production [60]. In type 1 diabetes (T1D), 
T cell mediated destruction of beta cells is accompanied 
by trans- and de-differentiation of beta cells to glucagon-
producing alpha cells [61]. NGN3 is an important regulatory 
transcription factor involved in neurogenesis; it is essential 
for endocrine cell fate specification in multipotent intestinal 
progenitor cells [62]. NGN3 positive cells obtained from 
exocrine cultures have characteristics typical of endocrine 
progenitor cells during early-stage development [63].
TWEAK-Fn14 interaction in healthy adult mice induces 
proliferation of ductal cells which are part of the pancre-
atic epithelial lining involved in the transfer of exocrine 
enzymes from acinar cells into the duodenum [64, 65]. It 
also induces transient NGN3 expression in the healthy nor-
mal adult mouse pancreas and those NGN3 positive cells 
do not express islet hormones [65]. Similar observations 
can be made in the early stages of pancreatic develop-
ment in embryos [65]. TWEAK-Fn14 interaction could 
potentially facilitate the production of new endocrine beta 
cells by de-differentiating ductal cells into progenitor cells 
expressing NGN3 (Fig. 2a) [65]. Those cells could through 
normal cellular machinery undergo neogenesis, become 
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Fig. 2  Proposed mechanisms of 
the TWEAK/Fn14/CD163 axis 
in the context of diabetes. In 
normal homeostatic conditions 
(a) TWEAK/Fn14/CD163 axis 
of interaction in pancreatic 
cells, adipose and muscle cells 
shows a protective role which 
allows for generation of new 
endocrine cells, cellular repair, 
protection from insulin resist-
ance, regulation of cell cycle 
and apoptosis. In inflammatory 
conditions observed during 
chronic hyperglycaemia (b) 
there is an observed increase in 
infiltration by TWEAK express-
ing macrophages, increase in 
CD163 expressing monocytes 
and increase in Fn14 receptor 
expression. Detected plasma 
sTWEAK concentration is 
lower in persons with diabetes. 
It is proposed that CD163 scav-
enges sTWEAK to inhibit its 
interaction with Fn14 and stop 
downstream interactions. These 
processes lead to apoptosis, 
reduction in insulin production 
and sensitivity. Shaded boxes 
indicate the final observed effect 
of TWEAK signalling
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new beta cells and restore insulin production [65]. This 
study has not however, addressed the effect of hypergly-
caemia or inflammation on the TWEAK-NGN3 relation-
ship and has not described the role of NGN3 at each stage 
of cellular maturation. Proinflammatory cytokines (TNFα, 
IL1β, and IFNγ), which are upregulated in the diabetic 
environment also upregulate NGN3 in human ductal cells 
via STAT3 signalling and this upregulation is persistent 
[66]. In this case, the prolonged NGN3 stimulation by 
cytokines in a chronic inflammatory environment such 
as diabetes appears to retain cells in an undifferentiated 
condition and prevent the formation of insulin positive 
ductal cells [66].
Obesity drives type 2 diabetes (T2D) development [67, 
68]. There is drastically less circulating sTWEAK in the 
plasma of people with T2D, yet, TWEAK gene expression 
in subcutaneous adipose tissue is not affected by obesity 
with Fn14 expression being detected only in patients with 
a BMI > 38 kg/m2, [33, 69]. The adipose tissue plays an 
important in the maintenance of energetic homeostasis and 
can quickly respond to changes in caloric intake via adi-
pocyte hypertrophy and hyperplasia [70]. The increase in 
adipose tissue observed during obesity has been shown to 
encourage several cell intrinsic behaviours such as adipocyte 
apoptosis, hypoxia, mechanical stress, abnormal secretion of 
chemo-attractants and consequential triggering of inflam-
matory responses [71]. Increased macrophage recruitment 
is observed alongside an increase in adipocyte death [72]. 
Macrophages make up to 40% of all adipose tissue cells 
in obese subjects [72]. TNFα, another member of the TNF 
superfamily, is significantly increased in the subcutaneous 
adipose tissue of morbidly obese people with and without 
T2D [69]. TNFα is a potent inducer of the NF-κB pathway, 
leading to insulin resistance and an increased inflamma-
tory state, which are chronically observed in obese subjects 
[73]. Despite this, a reduction in circulating TNFα does not 
restore insulin sensitivity in people with T2D [74]. Obese 
adipose tissue is infiltrated by macrophages which are a 
source of mTWEAK and sTWEAK [33]. sTWEAK is a 
negative feedback regulator of TNFα signalling, predomi-
nantly through TRAF2 [33]. sTWEAK has been shown to 
protect from insulin resistance by down regulating the TNFα 
induced increase in the activity of Protein phosphatase 2 
(PP2A) (Fig. 2a) [33]. Nutritional therapies and bariatric 
surgery are at present the most common and effective meth-
ods of fighting obesity [75]. Currently, there are no studies 
showing implementation of sTWEAK as an adjunct therapy 
to nutritional changes. However, in 69% of bariatric surgery 
patients, there was an increase in previously downregulated 
sTWEAK levels thereby hindering TNFα intracellular sig-
nalling events and lowering inflammation [76]. This sug-
gests that TWEAK could act as a post-bariatric surgery anti-
inflammatory therapy to aid in recovery.
In the study by Simon-Muela et al. gestational diabetes 
mellitus has also been connected with lower levels of cir-
culating sTWEAK [77]. Yet, CD163 or CD163/sTWEAK 
were negatively associated with HOMA‐IR [77]. Interest-
ingly, downregulation of TWEAK in uterine natural killer 
cells (uNK) of pregnant rats (which are the most common 
lymphocytes present during the early stages of gestation) 
and subsequent exposure to LPS leads to changes in cyto-
toxicity of those cells which encourages foetal rejection [16]. 
This suggests the role of TWEAK in maintaining homeo-
stasis is needed for successful pregnancy. Lower levels of 
sTWEAK were also associated with depression in people 
with T1D compared to those with T1D without depression 
[78]. There is no clear mechanism available which would 
describe how sTWEAK levels are depleted. Some studies 
have suggested that the scavenger receptor CD163 is upregu-
lated in the presence of pathologies characterised by chronic 
inflammation such as atherosclerosis and T2D allowing it to 
neutralise the biological activity of sTWEAK [79, 80]. The 
topic remains controversial as contradictory reports have 
been put forward questioning if CD163 concentration is a 
meaningful measure of metabolic syndrome and low grade 
inflammation [20, 79–81].
The controversy surrounding TWEAK and its receptors is 
further deepened by studies showing that TWEAK-transgenic 
mice have significantly higher body weight/fat mass in 
addition to increased insulin resistance and that TWEAK 
may promote poor disease outcomes in metabolic patholo-
gies (Fig. 2b) [82]. Similar observations have been made for 
nephropathy/diabetic nephropathy where TWEAK admin-
istration exacerbated renal damage in ApoE-knockout mice 
[82]. However, patients with diabetes undergoing haemodi-
alysis showed low levels of TWEAK [83, 84]. The studies 
propose that TWEAK binds to Fn14 with increased mag-
nitude, as the expression of the receptor is increased, and 
remainder of TWEAK is being scavenged by CD163 effec-
tively leading to lower detection levels in plasma [83, 84].
The use of resveratrol decreases CD163 expression 
which has been shown to increase levels of sTWEAK in 
people with T2D [85]. Resveratrol also increases expression 
of SIRT1 and 5′ AMP‐activated protein kinase (AMPK), 
which together inhibit NF‐κB and therefore, further increase 
sTWEAK concentration [46, 85]. The increase in sTWEAK 
was connected to increased expression of p53 and p21 genes 
required for inhibition of apoptosis, cell cycle regulation and 
tumour suppression [46, 85].
6  Tweak and cardiovascular disease
Over 75% of diabetes-related mortality is due to cardio-
vascular disease [86]. Cardiovascular diseases are associ-
ated with atherosclerosis which is an inflammatory disease 
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recognised by an abnormal accumulation of macrophages in 
the walls of the blood vessels [87]. Macrophages can display 
pro- or anti-inflammatory effects dependent on their polari-
sation state, which is a significant factor in the development 
of atherosclerotic plaque [88]. Similar to other inflammatory 
diseases, the detectable sTWEAK concentration is signifi-
cantly lower in patients with carotid atherosclerosis, coro-
nary and peripheral artery disease, atherosclerosis caused 
by T2D, and end stage renal disease [83]. CD163 levels are 
increased in those patients, however. CD163 has been rec-
ognised as an atherosclerotic plaque modulator due to its 
anti-inflammatory and anti-atherogenic abilities [89, 90]. It 
is, however, worth noting that numerous diseases such as 
acute kidney injury, autosomal dominant polycystic kidney 
disease and rheumatoid arthritis display upregulation of both 
TWEAK and Fn14 [36, 91–93]
There is a negative correlation between sTWEAK and 
IL6, and together with the low-grade inflammation score, 
which in turn is associated with arterial stiffness, is an early 
precursor to atherosclerosis [59]. In some studies, CD163 
concentration has also been associated with inflammatory 
markers [20]; however, Llaurado et al., did not observe this 
in their cohort, with CD163 only displaying a modest associ-
ation with low sTNFαR2 exclusively in males [59]. Despite 
this, a CD163 deficiency appears to have a negative impact 
on the atherosclerotic outcome in mice models. ApoE/
CD163 double-deficient mice displayed bigger plaques, 
greater instability in their atherosclerotic plaques, elevated 
lipid-macrophage concentration, and higher expression of 
pro-inflammatory cytokines [94]. The same study demon-
strated that CD163 deficient M2 macrophages resulted in 
greater foam cell formation via the upregulation of CD36. 
Direct blockage of the TWEAK/Fn14 pathway significantly 
decreases the uptake of oxidised low-density lipoprotein by 
macrophages, which reduced foam cell formation, but this 
is not regulated by changes in CD36 expression [95]. Inter-
estingly foam cells themselves express Fn14, yet TWEAK/
Fn14 interactions on their own do not control apoptosis of 
macrophage foam cells in vitro. Furthermore, Fn14-Fc treat-
ments in vivo, do not affect apoptotic rates in atheroscle-
rotic plaques [95]. Increases in apoptosis are only observed 
when the cells are stimulated with a cytomix of TWEAK 
and TNFα [95].
Addition of recombinant CD163 diminishes the migra-
tion of macrophages induced by supernatants from VSMCs 
stimulated with TWEAK [94]. This falls in line with previ-
ous studies where blocking of TWEAK encouraged cell 
migration in vitro yet at the same time alleviated the num-
ber of cells infiltrating into diseased tissue. This suggests 
that TWEAK regulates chemokine gradients, adhesion 
and cell migration dependent on the environmental con-
ditions [95, 96]; the mechanism behind this dual action is 
not known. Gutierrez-Muñoz et al. also state that CD163 
expressing macrophages exert a protective role by block-
ing TWEAK’s effect on atherosclerosis development and 
progression (Fig. 3) [94]. There is evidence however, that 
soluble Fn14, which is upregulated during inflammation, 
can inhibit TWEAK/CD163 interaction [3, 97]. Binding 
of CD163 to TWEAK does not denature the protein or 
stop its activity, but instead activates different downstream 
pathways like Notch signalling needed for repair [21]. 
There is little information available on the behaviour of 
TWEAK and its mechanism of action in the context of ath-
erosclerotic inflammation and metabolic disease in various 
cells; however, it could be speculated that increases in 
CD163 act to counteract increased Fn14 expression and 
competitively bind to TWEAK to simultaneously encour-
age potential beneficial CD163-TWEAK interactions 
and negate negative Fn14-TWEAK interactions. Studies 
suggest that TWEAK has no effect in plaque initiation 
but instead exerts its effects in the later stages of already 
developed atherosclerosis [27, 95]. This could be influ-
enced by the increased pool of other cytokines, such as 
TNFα. TNFα is actively involved in the progression of ath-
erosclerosis and influences TWEAK/Fn14/CD163 activity, 
which through regulatory cascades, leads to worse athero-
sclerotic outcomes [98]. In fact, Fernández-Laso et al. who 
focused on the direct effect of TWEAK on atherosclerosis 
in diabetic mice (rather than that of the receptors), pro-
poses that the reduction in the presence of inflammatory 
cells (mostly macrophages) in lesions of TWEAK deficient 
diabetic mice is due to decreased activation of JAK/STAT, 
NF-κB, and the expression of proinflammatory cytokines 
[55]. This was also the first study to show that hypergly-
caemia induces TWEAK to display its pro-atherosclerotic 
behaviour by partially inhibiting STAT1 and consequently 
upregulating the expression of proinflammatory target 
Fig. 3  Proposed mechanism of the TWEAK/Fn14/CD163 axis in the 
context of cardiovascular disease. TWEAK/Fn14/CD163 have been 
implicated in the development of CVD with a large focus on athero-
sclerotic plaque formation and development. Similar to other inflam-
matory pathologies, in atherosclerosis, there is increased infiltration 
by TWEAK expressing macrophages, increased CD163 expressing 
monocytes and increased Fn14 receptor expression. The concentra-
tion of sTWEAK is also reduced. It is proposed that CD163 binds to 
TWEAK, which stops macrophage migration and further infiltration. 
It also helps in maintenance of plaque stability and size although the 
downstream pathway responsible for this is not known. Initial plaque 
development is independent of TWEAK, but through the interaction 
with Fn14 and presence of other cytokines, TWEAK impacts estab-
lished plaques leading to an increase in plaque size and instability, 
which is largely driven by foam cell formation and angiogenesis. Ath-
erosclerosis can lead to several cardiovascular complications such as 
myocardial infraction and heart attacks. There is some evidence that 
TWEAK/Fn14/CD163 is involved at the sites of the acute injury 
caused by cardiovascular (CVD) and is largely used for repair and 
not further damage. Shaded boxes indicate the final observed effect of 
TWEAK signalling
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genes including CCL5, CXCL10 and ICAM-1. TWEAK 
functioning through STAT1 is an interesting discovery. 
There is evidence that STAT1 plays a significant role in 
beta cell death, T-cell immunoregulation, and develop-
ment of autoimmune pathologies such as T1D [99]. The 
mechanism by which STAT1 gain of function encourages 
autoimmunity is not known but it has been put forward 
that faulty lymphocyte activation and signalling are the 
key culprits [99]. In fact, use of JAK inhibitors to inhibit 
STAT1 show improvement in NK cell function, and dys-
regulated T-cell polarisation in patients with STAT1 gain 
of function mutations [100].
The TWEAK/Fn14 pathway appears to be involved in 
cardiac inflammation in non-ischemic stress conditions 
(Fig. 3). Unudurthi et al., have demonstrated that it is the 
Fn14 receptor which mediates pressure overload-induced 
heart failure, macrophage infiltration in hearts exposed to 
this kind of pressure, and that its inhibition can effectively 
reduce the pathological remodelling and prevent further car-
diovascular complications to some extent [101]. This study 
has also shown that increases in MCP-1 secretion in car-
diac fibroblasts is mediated by the TWEAK-Fn14 pathway 
partially through engagement of the non-canonical NF-κB 
pathway [101]. MCP-1 through its chemotactic inducing 
abilities encourages passage of monocytes from the lumen 
to subendothelial space where they convert into foam cells, 
which eventually leads to atherosclerotic plaque formation 
[102]. Interestingly, increases in the available circulating 
plasma MCP-1 have also been connected with increased 
long-term risk of stroke [103]. Recent studies have likewise 
shown that secreted MCP-1 regulates the angiogenic effect 
of tissue factor by recruiting smooth muscle cells toward 
endothelial cells and enables the maturation of newly formed 
micro vessels [104].
Atherosclerosis can also lead to acute myocardial infrac-
tion (AMI) which is one of the leading causes for death world-
wide [105]. Similar to atherosclerosis, plasma sTWEAK 
expression is significantly higher in patients who suffered 
from AMI. However, in this instance, TWEAK encourages 
beneficial endothelial progenitor cell (EPC) vasculogenic 
properties to relieve acute myocardial infarction via the 
Fn14-NF-κB signalling pathway and additionally increases 
the migration of EPC to the site of injury [106]. Although not 
directly related to cardiovascular disease (CVD), it is worth 
mentioning that TWEAK/Fn14 activation has been shown to 
induce beneficial migration and cytokine production of both 
dermal microvascular endothelial cells and dermal fibroblasts 
in burn wounds [46]. What is interesting is that TWEAK 
mediates and increases the expression of α-SMA and palladin 
in dermal fibroblasts during repair [46]. Recent studies have 
made a connection between reduced levels of α-SMA and 
increased abdominal aortic aneurysms [107]. It is speculated 
that abdominal aortic aneurysms (although not often consid-
ered a ‘standard’ cardiovascular disease) are largely caused 
by atherosclerosis [108].
The expression of TWEAK/Fn14 in healthy human brain 
and their regulation in inflammatory and neurodegenerative 
diseases are yet to be characterised. There is, however, evi-
dence that TWEAK/Fn14 plays a role in stroke development 
[109]; CD163 has not been well investigated in this context. 
There is a sharp upregulation of sTWEAK concentrations 
and Fn14 expression in ischemic stroke patients with the 
concentration of TWEAK returning to normal within 24 h 
after a stroke event [109, 110]. Light induced increases of 
Fn14 in the thalamocortical excitatory neurons and up- 
regulation of TWEAK in microglia is required for the 
removal of weak synapses and fortifying of the remainder, 
which is required for correct synapse maturation [111, 112]. 
The role of TWEAK/Fn14 outside of synapses is however, 
poorly understood. In the study by Nagy et al. it was dem-
onstrated that inhibition of TWEAK/Fn14 is beneficial post 
ischemic stroke as it appears to limit synaptic degradation 
and increase basal synaptic transmission and plasticity in 
Fn14KD mice [5]. Other cytokines such as IL1β and TNFα 
can also be found at the site of injury post ischemic stroke 
[113]. Interestingly TWEAK cannot induce synaptic apop-
tosis on its own unless other cytokines such as TNFα and 
IFNγ are present [1, 5].
7  Conclusions
The general theme of current research suggests that chronic 
inflammation is the main causative agent which causes 
TWEAK to behave erroneously and propagate inflamma-
tion-driven cellular degradation. Significantly more work 
is required to understand the role of the TWEAK/Fn14/
CD163 axis alongside other inflammatory cytokines in the 
context of diabetes. Despite increases in research investi-
gating TWEAK and its receptors, especially in the cardio-
vascular setting, a lot of questions remain unanswered. It 
is unknown if membrane bound TWEAK has a different 
effect on signalling and its ability to bind to neighbour-
ing Fn14 receptors or even CD163. Furthermore, a deeper 
understanding on the preferential activation of pathways to 
induce certain cellular behaviours in different tissue types 
is required. In fact, there are very few studies investigating 
the effect of the TWEAK/Fn14/CD163 axis in brain, heart 
or pancreas, before the complexities of extrinsic cellular fac-
tors are included. TWEAK/Fn14/CD163 undoubtably has 
therapeutic potential, yet there is a need to establish what 
factors cause the switch in the function of TWEAK from 
protective to damaging.
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